News

PipelineReview.com5h
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
SHANGHAI, China I May 15, 2025 I Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for ...
PipelineReview.com5h
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency ...
PipelineReview.com1d
Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...
PipelineReview.com1d
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
SEONGNAM, South Korea I May 15, 2025 I Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today ...
PipelineReview.com1d
Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data
MENLO PARK, CA, USA I May 14, 2025 I Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company developing novel immunomodulatory therapeutics ...
PipelineReview.com1d
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
PARAMUS, NJ, USA I May 14, 2025 I NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food ...
PipelineReview.com1d
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
Title: ATYR0101: A New Approach to Fibrosis Presenter: Ryan Adams, Ph.D., Senior Director, In Vitro Biology Session: Showcase Three: ILD/Fibrosis Date and Time: Saturday, May 17, 2025 at 11:30 AM PT ...
PipelineReview.com10d
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
SOUTH SAN FRANCISCO, CA, USA I May 6, 2025 I IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company ...
PipelineReview.com1mon
Sabin Begins Marburg Vaccine Trial in U.S.
WASHINGTON, DC, USA I April 16, 2025 I The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the first ...
PipelineReview.com1mon
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I April 16, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 ...
PipelineReview.com5d
Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
LONDON, UK I May 12, 2025 I Leucid Bio ("Leucid" or "The Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric ...
PipelineReview.com1mon
Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid Malignancies
BOSTON, MA, USA I April 15, 2025 I Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today announced that ...